MS SR21

Recognizes that African-American men face disproportionately higher prostate cancer risk, with one in six developing the disease in their lifetime compared to one in nine for white men.

Notes that African-American men are 1.7 times more likely to be diagnosed with prostate cancer and 2.3 times more likely to die from it than white men, with diagnosis at more advanced stages.

Identifies race, age, and family history as a triple risk factor for older African-Americans developing prostate cancer.

Encourages culturally competent outreach efforts to educate communities of color on early detection importance and urges African-American men to participate in clinical trials.

Calls on clinical trials to actively recruit African-American men to improve patient outcomes and access to medical advances.